A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Momelotinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences; Sierra Oncology
- 17 Apr 2017 Status changed from active, no longer recruiting to discontinued.
- 03 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2017.
- 21 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.